An accurate and low-risk diagnostic test for coronary artery disease European consortium tests computed tomography as an alternative to cardiac catheterization Peer-Reviewed Publication ...

Using a CAD polygenic risk score including 241 genome-wide significant single-nucleotide variations, researchers defined polygenic risk for CAD as low (bottom 20%), intermediate or high (top 20%).

In patients with stable chest pain and intermediate pretest probability of CAD, risk for major adverse CV events was similar after CT or invasive coronary angiography, with fewer procedure-related ...

Entry required them to be at intermediate risk, defined as an estimated 10% to 60% probability of having obstructive CAD. Of note, women made up about 56% of both groups.

MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...

An increasing number of doctors are encouraging patients -- especially those deemed to be at high-risk for developing CAD -- to undergo a noninvasive imaging procedure called coronary computed ...

It seems that CAC assessment may be useful in symptomatic patients who have a low-to-intermediate pretest risk of CAD or in patients with equivocal stress-testing findings.

Traditionally, most CAD risk assessment tools and tests have been validated on a relatively narrow population, according to Akash Kumar, MD, PhD, chief medical and scientific officer of MyOme.

The team is pioneering this app-based approach. They developed a free CAD-risk iPhone app, as well as an Android app. Users can link their existing 23andMe data and fill out consent forms and ...

PARIS, France—Patients with severe symptomatic aortic stenosis (AS) and stable intermediate CAD undergoing TAVI may be at lower risk of MACE when coronary revascularization is guided by fractional ...

Monday, May 12, 2025. News & Perspective Drugs & Diseases CME & Education Video Decision Point Drugs & Diseases CME & Education Video Decision Point ...

MyOme Launches Integrated Risk Tool for Coronary Artery Disease MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling ...